OptiNose has appointed Tom Gibbs as Chief Commercial Officer to oversee the commercialization strategy for EDS-FLU (OPN-375) intranasal fluticasone, which is in Phase 3 development for the treatment of nasal congestion in patients with nasal polyposis. Gibbs was most recently Senior VP and Head of the General Medicines Business Unit, US for Takeda.
Gibbs said, “I believe deeply in the potential of EDS-FLU to transform the treatment of chronic rhinosinusitis and improve the lives of the millions of patients suffering from the disease. The results of the Phase 3 trials were exceptional, but what cemented my decision to join the great team at OptiNose was the inspiring personal testimonials I heard from patients regarding how EDS-FLU made a significant difference in their lives. I am thrilled to join the company at such an incredibly exciting time, and look forward to leveraging my diverse skills and experiences to bring this important product to patients.”
OptiNose CEO Peter MIller commented, “As we transition from a development based company, to a commercial stage company, OptiNose is at a critical stage. Tom is a highly respected commercial leader with a reputation for innovative thinking, building strong teams and delivering superior results. The breadth and depth of Tom’s commercial experience with various companies and across many therapeutic areas, along with his diverse background and proven track record make him superbly qualified to grow and to lead OptiNose’s commercial organization.”
In October 2015, the company announced that it had raised $30 million for development of OPN-375.
Read the OptiNose press release.
